a0262 7june ms ar 16pgs - mount sinai hospital · of our labs is developing a blood test to...

200 4-0 5

Research is the

bestme d i c i neAnnual Report

Samuel Lunenfeld Research Institute

1

Our anniversary celebration, Decades ofDiscovery, was a reflection on the remarkablegrowth of the slri, and a springboard forour exciting future. At this dynamic time inmedical history, when the mapping of thehuman genome has enabled better under-standing of the causes of common andchronic diseases, research is the foundationof innovative medicine, leading to newtreatments and ensuring a higher level ofpatient care. Our continuing quest is to find the underlying genetic answers tosociety’s most pressing health problems.

Over the years, the slri has grown inboth size and reputation, and is now

considered one of the top ten biomedicalresearch centres in the world. From itsfounding in ı985 under the Directorshipof Dr. Lou Siminovitch, to successor Dr. Alan Bernstein, and under the exceptional recent leadership of Dr. TonyPawson, the slri focuses the efforts ofsome of the world’s brightest mindstoward improving people’s lives. At theend of 2oo5, Dr. Pawson completed anoutstanding five-year term as Director andwe thank him for his leadership. We arealso delighted that Tony will remain withthe slri, continuing his pioneeringresearch on how cells communicate with

Welcome to the annual report of world-renowned SamuelLunenfeld Research Institute (slri) at Mount Sinai Hospital,which, in 2oo5, celebrated 2o years of conducting leading-edge research – the building blocks of new treatments andtherapies that will ultimately improve outcomes and qualityof life for our patients.

Message from Mount Sinai HospitalContents

ı Message from Mount Sinai Hospital

2 Message from the SLRI Leadership

5 Centre for Modeling Human Disease

6 Auxiliary Centre for Women’s and Infants’ Health

9 Centre for Stem Cells and Tissue Engineering

ı ı Centre for Neurodevelopment and Cognitive Function

ı2 Centre for Genomic Medicine

ı4 Fred A. Litwin Centre for Cancer Genetics

ı7 Centre for Systems Biology

ı9 Prosserman Centre for Health Research

2o Quick Statistics 2oo4-o5

22 SLRI Leadership 2oo4-o5

23 Samuel Lunenfeld Research Institute

3

one other. We are pleased to welcome anew Director of Research, Dr. JamesWoodgett, a world-class scientist mostrecently with the Ontario Cancer Instituteat Princess Margaret Hospital. Jim saysthat he is “honoured to follow such aremarkable immediate predecessor as TonyPawson; I hope to live up to his standardsand to inspire all of the Institute’s scientists –and to be inspired by them.”

With over 7oo staff, more than ı25,ooosquare feet of lab space, and a $64-millionbudget (2oo4-o5), the slri is committedto discovering and delivering the bestresearch, which, in turn leads to the bestpatient care. It’s a complex, challenging,yet extremely rewarding task, as we worktirelessly to expedite the journey frombench to bedside.”

Our award-winning researchers are takingsteps every day toward a better under-standing of chronic illnesses such as cancer,gastrointestinal disease, heart disease,

arthritis, and diabetes, as well as makingimportant strides in other areas such aswomen’s and infants’ health.

Please enjoy this publication, whichilluminates just some of the wonderful scientists and the work of the variouscentres comprising the Samuel LunenfeldResearch Institute. The slri has a proudhistory, and an ambitious goal ahead,aimed at improving people’s lives now –and in the future.

Sincerely,

Lawrence BloombergChair of the Board of Directors

Lawrence TanenbaumCo-Chair of the Research Committee

Joseph MapaPresident and CEO

Thomas KieransCo-Chair of the Research Committee

pictured previous page, l to r

The scientists in the slri range from thosemaking profound new discoveries about thefunctions of cells and their organization intotissues, to those who directly apply suchnew discoveries to treat individual patients,or to prevent disease in the community atlarge. Fundamental science can reveal the

way a gene, a protein, or a drug functions inthe body, uncover previously unimaginedways in which our cells work, and identifyeffective new targets for therapy. Withoutthese intellectual advances, medicine itselfcannot progress. Importantly, through the intimate association of the slri and

Canadians tend to be modest by nature, and it is sometimeshard to appreciate that one of the very best biomedical researchinstitutes in the world, the Samuel Lunenfeld Research Institute,is located right here in Mount Sinai Hospital.

Message from the SLRI Leadership

Mount Sinai Hospital, and the interminglingof basic scientists, clinical scientists, epidemiologists, and physicians, we have aunique opportunity to learn how to bettercombat human disease. Any disease, nomatter how complex and devastating it mayappear, has as its root cause one or a fewunderlying aberrations that we can discoverand treat.

One of the great virtues of the Instituteis that it is rather small, encouraging collaboration. Our ability to secure peer-reviewed research funds has continued toescalate at an astonishing rate. As a fewexamples, we received $ ı5m from theCanada Foundation for Innovation for newequipment and towards an expansion of theInstitute in the area of Systems Biology,Andras Nagy has been highly funded for hisexciting work on human stem cells, JamesDennis heads a Canadian Institutes ofHealth Research (cihr) funded team projectthat will investigate the genetic differencesamong patients who are sensitive or resistantto the sars virus, and Genome Canada will support a $ ı2m project on proteininteractions, in collaboration with theUniversity of Western Ontario. In the lastcihr grants competition we received$6.9m, almost exactly the same as very muchlarger research enterprises in Toronto.

Indeed, younger scientists are the lifeblood of any research institute. We arevery excited about the recruitment of twooutstanding investigators, both of whombring new scientific expertise and vigour.Helen McNeil comes from CancerResearch uk in London, and is an expert in the genetics of cellular organization.Anne-Claude Gingras trained at McGillUniversity and at the Institute for SystemsBiology in Seattle, and is an authority in

the field of proteomics (the comprehensiveanalysis of proteins), and in the cellular path-ways that control cell growth, with importantimplications for cancer and diabetes.

Importantly, the successes of the slri have depended on the support and commitment of the Hospital and ResearchBoards, and their approval to renew theInstitute through an expansion on theLebovic site is a remarkable visionarydevelopment.

It has been an exciting time to lead theInstitute. Please venture through the following pages and learn how our scientists’research enables medicine at home andaround the world.

Professor Anthony J. Pawson, frsDirector of Research Samuel Lunenfeld Research Institute

Dr. Stephen J. Lye, ph. d.Associate DirectorSamuel Lunenfeld Research Institute

2

“

5

To state the obvious, mice are not men. Yet, from a geneticpoint of view, they are remarkably similar. Researchers at theCentre for Modeling Human Disease are using the mouse to model and understand a wide range of human diseases.

Centre for Modeling Human Disease

We share more than 9o percent of our geneswith the mouse,” explains Dr. Janet Rossant,Co-ordinator of the Centre. “Knowingwhat a gene does in the mouse, and whathappens if that gene is altered or mutated,can give us insight into the effect the samegenetic alteration would have in humans.”

Whether a mouse has osteoporosis,heart problems, or some other disease,researchers at the Centre can often findthe gene involved. Then, they can explorewhether the same gene is involved in thehuman disease. Or, if a gene is importantin a human disease, they can make a mouse that lacks that gene and explorewhat happens to its health. Then, usingspecial equipment, scientists can monitorthe mouses’s blood pressure and bloodchemistry or even perform mri and ultra-sound scans on it.

While human diseases don’t always have thesame symptoms as their mouse equivalents,they are often very similar. “In cases wherethey differ, the mouse has usually developedsome genetic ‘coping mechanism’ to makeup for a particular defect,” explains scientistDr. Sabine Cordes. “Finding out how themouse avoids the disease can give us insightsinto how to prevent it in humans.”

Researchers at the Centre have alreadydeveloped mouse models for kidney disease,epilepsy, and a human syndrome thatcauses developmental anomalies. Researchgroups across Toronto use the Centre’smice to model a range of human diseases,including bone, blood, and cardiovasculardisorders. “This will open up exciting newpossibilities for studying the genetics ofhuman diseases,” says Dr. Rossant.

“

Quick facts aboutthe Centre forModeling HumanDisease

Number of staff: 60

Funding sources: Canadian Institutes ofHealth Research (cihr)

Canada Foundation forInnovation(cfi)

Genome Canada

Industrial partners

Dr. Janet Rossant (Co-ordinator)

Dr. Lee Adamson

Dr. Alan Bernstein

Dr. Sabine Cordes

Dr. George Fantus

Dr. Marc Grynpas

Dr. Colin McKerlie

Dr. Andras Nagy

Dr. Susan Quaggin

Dr. John Roder

Dr. William Stanford

Investigators with primary appointments:

Finding out how themouse avoids a disease cangive us insights into how toprevent it in humans”Dr. Sabine Cordes

“

6

Scientists at the Auxiliary Centre for Women’s and Infants’Health are studying the earliest stages of human life. Their research into reproductive biology, pregnancy, and the transition to the newborn period is paving the wayfor medical advances on several key fronts.

Auxiliary Centre for Women’s and Infants’ Health

A good deal of our research focuses on the placenta, the structure that nourishes the fetus during development,” explainsDr. Lee Adamson, Centre Co-ordinator.The placenta regulates maternal changesduring pregnancy and provides the nutritionand environment that allow the embryo todevelop. It is vital to pregnancy, and so it’sa subject of considerable attention here.”

Scientists at the Centre are also studyingpre-eclampsia and intra-uterine growthrestriction, two major disorders that canoccur during pregnancy. Both can be life-threatening and neither can currentlybe treated effectively.

Premature delivery is another researchfocus. “We don’t really know how to stoplabour when it starts too early,” says Dr.Adamson. “In about 5o per cent of cases,pre-term labour stops spontaneously. Oneof our labs is developing a blood test to

differentiate women who really will deliverprematurely from those who won’t.”

Some of the Centre’s research into earlydevelopment has implications for adults.We’re learning that people who do nothave an optimum early environment aremore likely to have diabetes, heart disease,osteoporosis, and other problems as adults,”says Dr. Adamson.

In addition to serving as a research hub,the Centre hosts a tissue bank containingsamples of placenta, blood, and other tissues. This is an invaluable resource forscientists needing access to large numbersof tissue samples for genetic research.

Promoting interaction between cliniciansand basic researchers is a major objective at the Centre. The goal is to ensure that newknowledge gained from research is quicklytranslated into medical practice.

“

“

Quick facts aboutthe Auxiliary Centrefor Women’s andInfants’ Health

Number of staff: 106


Heart and StrokeFoundation of Canada

March of Dimes

Mount Sinai HospitalAuxiliary

National Insitutes ofHealth (nih)

Dr. Lee Adamson (Co-ordinator)

Dr. Theodore Brown

Dr. Isabella Caniggia

Dr. Robert Casper

Dr. Stephen Lye

Dr. Susan Quaggin

Dr. Janet Rossant


“

We’re learning that people who do not have an optimum early environment are more likely to have diabetes, heart disease, osteoporosis, and other problems as adults”Dr. Lee Adamson

“

9

Centre for Stem Cells and Tissue Engineering

Many diseases damage vital tissues. Heartattacks often kill cardiac muscle, while arthritiseats away joint cartilage. Autoimmunereactions can lead to the destruction ofvitally important cell types, as is the case indiabetes and multiple sclerosis. Accidentscan lead to damage of spinal cord cells. All these and many more conditions cannotbe cured with medication and techniquesavailable to us today. Our hope for thefuture lies in using stem cell based therapiesfor these devastating conditions. Instead of giving drugs to treat symptoms, stem celltherapy aims at actually repairing damagecaused by disease or trauma to organs and tissues. “We hope to one day be ableto offer a real cure for the many peoplesuffering from conditions that are nowconsidered incurable,” says Dr.Andras Nagy,Co-ordinator of the Centre.

In many cases, replacing cells alone isnot enough to give a cure.The joint, for

example, is very complex in terms of its cells,shape, and structure. Scientists are workinghard on finding ways to help stem cellsproperly form these intricate structures.Using a technique called tissue engineering,scientists at the Centre are trying toregenerate these complex tissues. “Thesetechniques may help us to one day rebuildwhole organs,” explains Dr. Nagy.

Stem cells hold great promises for manypeople around the globe now desperatelywaiting for us to give them a cure. It is ourobligation to humankind to make our besteffort to bring these new hopes to realityas soon as possible.

The Centre leadership is well aware that this can only be done if all researcherswork hard together. “We support this goal by making our stem cells available tolaboratories in Canada and around theworld,” says Dr. Nagy.

Quick facts aboutthe Centre for StemCells and TissueEngineering



The Stem Cell Network

Specific disease-relatedsocieties

Dr. Andras Nagy (Co-ordinator)

Dr. Alan Bernstein

Dr. Robert Casper

Dr. Sabine Cordes

Dr. Marc Grynpas

Dr. Rita Kandel

Dr. Susan Quaggin

Dr. Janet Rossant

Stem cells haven’t made up their minds what to be when they grow up. They have a great ability to develop into manykinds of cells, and to replace cells damaged by accident ordisease. Harnessing the potential of these versatile cells toimprove human health is the research focus of the Centre for Stem Cells and Tissue Engineering.


We hope to one daybe able to offer a realcure for the many peoplesuffering from conditionsthat are now consideredincurable”Dr. Andras Nagy

“

11

Centre for Neurodevelopment and Cognitive Function

We’re trying to understand which moleculesare required for the nervous system tofunction and how they affect the wholerange of brain functions, from learning tomood disorders,” explains Dr. Mei Zhen,Co-ordinator of the Centre. “For example,researchers here are working with mice withspecific cognitive defects. These producemental illnesses very similar to those foundin humans.”

Research teams have produced mousemodels for schizophrenia, depression, andanxiety that have already made significantcontributions to understanding how thebrain functions. In the near future, ourscientists will continue to identify andstudy genes directly related to humanmental health.

“We are working to understand what happens at the molecular level to peoplewith mental illnesses – the functions ofgenes associated with mental illness, whatproteins they produce, and how they causemental disorders,” explains Dr. Zhen. “Unlesswe really understand the specific genes that result in mental defects, there’s no wayto design really effective treatments. Nowthat we know what genes are involved, we are testing for drugs that target disease-related proteins we have identified. Thismay lead us to develop drugs for mental illnesses that will be tailored to individualpatient needs.”

Quick facts aboutthe Centre forNeurodevelopmentand CognitiveFunction

Number of staff: 88


Canada Foundation forInnovation (cfi)

National Institutes ofHealth (nih)

National Sciences andEngineering ResearchCouncil (nserc)

Private foundations

Dr. Mei Zhen (Co-ordinator)

Dr. Sabine Cordes

Dr. Joseph Culotti

Dr. Tony Pawson

Dr. John Roder

Mental illness and learning disabilities are major healthconcerns in Canada. At the Centre for Neurodevelopmentand Cognitive Function, researchers are learning moreabout disorders of the human brain by studying the nervoussystems of organisms ranging from worms to mice.


Once we know what genes are involved, we will be able to look for drugs that target disease-related proteinswe have identified”Dr. Mei Zhen

“

“

Centre for Genomic Medicine

Genomics involves large scale of genes andtheir functions,” explains Dr. KatherineSiminovitch, Co-ordinator of the Centre.We’re now entering an era of genomicmedicine, medical care based upon geneticknowledge. At the Centre, our goal is tofind genes that cause disease and to quicklyapply that information to improvingpatient care.”

Areas of research include rheumatoidarthritis, inflammatory bowel disease (ibd),and the inflammatory processes associatedwith various other diseases. A research teamat the Centre recently identified one of the genes responsible for ibd – a discoverythat will ultimately help doctors diagnose,classify, and treat ibd patients.

Teams at the Centre are also studying the genetics of many other common diseasesand disorders, including breast and coloncancer, infertility, diabetes, and host responsesto infectious pathogens such as sars and hiv.

“We don’t yet know the causes of manycommon diseases,” says Dr. Siminovitch.As a result, our treatments are not alwayseffective, and may have significant sideeffects. Moreover, we are unable to preventmost diseases. This situation can only bechanged by aquiring understanding of theroot causes of such illnesses.”

Because the focus of genomic medicineis on translating research findings intoclinical practice, the Centre fosters closecollaborations between basic scientistsand clinical researchers. “Physicians fromMount Sinai Hospital are key players onour research teams,” says Dr. Siminovitch.They help Mount Sinai provide the bestmedical care to patients by building onour work and translating discoveries madeat the Centre into clinical practice.”

Quick facts aboutthe Centre forGenomic Medicine

Number of staff: 86


Canadian GeneticDisease Network

Crohn’s and ColitisFoundation of Canada

Canadian ArthritisNetwork

Genome Canada

Private corporations

Dr. Katherine Siminovitch(Co-ordinator)

Dr. George Fantus

Dr. Steven Gallinger

Dr. Pamela Goodwin

Dr. Alexandra Logan

Dr. Susan Quaggin

Dr. Bernard Zinman


The Human Genome Project has unlocked a treasure troveof new information about human genetics. Researchers atthe Centre for Genomic Medicine are working to translatethis knowledge into innovative strategies to prevent, diagnoseand cure disease.

Our clinical research teamsallow Mount Sinai to provide thebest medical care to patients translating discoveries made at theCentre into clinical practice”Dr. Katherine Siminovitch

“

12

“

““

“

14

Fred A. Litwin Centre for Cancer Genetics

Our teams study cancer genetics at themolecular level as well as conducting animal and human studies,” says Dr. StevenGallinger, Co-Director of the Centre.We study common cancers like breast andcolorectal cancer, as well as less commonones, including pancreatic cancer, sarcoma,and endometrial cancer.”

Scientists already understand a great dealabout the genetic basis of common cancers.By studying genes that cause rare cancers,they are learning even more about thecommon forms.

Researchers at the Centre recently analyzed the frequency in the population of a gene linked to inherited colorectal cancer.Although the gene is relatively rare, its pres-ence has important implications for carriers.

To learn more about the genes involvedin cancer, researchers across the worldoften turn to the Centre’s BiospecimensRepository. This tissue bank containssamples from thousands of cancer patients

and healthy individuals taken over morethan a decade.

“The Repository is a fantastic resource,”says Dr. Gallinger. “New, high-throughputtechnologies allow us to analyze huge numbers of genes in tissue samples, lookingfor common patterns in people who hadcancer, and those who didn’t. We can look atmillions of variations in a genetic sequencein weeks. Until recently, the same taskwould have taken years.”

The Centre also serves a vital trainingfunction. Graduate students, postdoctoralfellows, and clinical fellows – the next generation of researchers – are importantmembers of its research teams. “Developingand attracting new talent is important to thefuture of this Centre,” says Dr. Gallinger.

“Because of the multi-disciplinary natureof the Centre, our trainees are exposed to basic laboratory science, epidemiology,biostatistics, and clinical research,” says Dr.Irene Andrulis, Co-Director of the Centre.

Quick facts aboutthe Fred A. LitwinCentre for CancerGenetics

Number of staff: 75

Funding sources:Canadian Breast CancerFoundation

Canadian Breast CancerResearch Association(cbcra)

Canadian Institutes ofHealth Research (cihr)


National Cancer Instituteof Canada (ncic)

National Institutes ofHealth (nih)Ontario Cancer ResearchNetwork

Mr. Fred A. Litwin

Terry Fox Foundation

Investigators with primary appointments:Dr. Irene Andrulis (Co-Director)Dr. Steven Gallinger (Co-Director)Dr. Bharati BapatDr. Hilmi OzcelikDr. Jay Wunder

Cancer is one of the leading causes of death in Canada – and thenumber of cases is rising. To design truly effective preventionstrategies and treatments, scientists must first try to understandthe genetic basis of cancer. That is exactly what researchers atthe Fred A. Litwin Centre for Cancer Genetics are doing.

Developing andattracting new research talent is important to the future of this Centre”Dr. Irene Andrulis andDr. Steven Gallinger

“

“

“

17

Centre for Systems Biology

We’re working to identify the molecularcircuitry controlling cell growth and otherfunctions critical to the development ofcancer and other major diseases,” explainsDr. Jim Dennis, Co-ordinator of the Centre.Our goal is to first understand the diseaseprocess, taking into account the entiremolecular environment of the cell. Then,we hope to target critical network nodesthat control the disease process.”

Inputs to these incredibly complex biological networks include nutrients andenvironmental factors. Network outputsare the behaviour of cells and, ultimately,the individual’s vulnerability to disease.

“We are using computational models of these molecular networks to enhanceour understanding of both normal cellfunction and disease processes,” explainsDr. Dennis. “In the future, we hope these

models will help doctors predict the likelycourse of diseases and choose the besttherapies for people, given their geneticmakeup and disease status.”

Because computation and mathematicalmodelling are key to the Centre’s work,researchers are integrating traditionallyseparate disciplines such as biology, genetics,and mathematics. Some teams are alsobuilding chemical libraries, to isolate com-pounds with specific cellular activities thatcan be used to treat diseases such as cancer.

One research team recently mappedthe interactions in signalling pathwayscritical to cancer cell growth. This willallow scientists to develop drugs that slowor stop cancer development by targetingthe cancer’s circuitry.

Quick facts aboutthe Centre forSystems Biology



Genome Canada



Private foundations

Dr. Jim Dennis (Co-ordinator)

Dr. Dan Durocher

Dr. Gerry Gish

Dr. Tony Pawson

Dr. Frank Sicheri

Dr. Mike Tyers

Dr. Jeff Wrana


Complex electrical devices are controlled by networks ofelectronic circuits. In the same way, cellular sub-components,cells, and larger, multi-cell structures are controlled by networks of interacting proteins, working in harmony tomaintain life. Studying and understanding these interactionsis the primary focus of the Centre for Systems Biology.

We are using computer models of these molecular networks to enhance our understanding of both normal cell function and disease processes”Dr. Jim Dennis

“

“

“

19

Prosserman Centre for Health Research

We can’t learn how to prevent serious illnessjust by looking at individuals,” explainsDr. John McLaughlin, Co-ordinator ofthe Centre. “Often, we can detect patternsof disease earlier using population studies.Our research helps healthcare officialsplan services and strategies for everyone.”

In addition to doing research, scientists atthe Centre are working to improve researchmethods. Biostatisticians have developednew methodologies – carefully crafted procedures and processes – to study complexdiseases. Using these new methodologies,scientists have made great progress inunderstanding a variety of illnesses.

“For example, one team has identifiedgenetic factors that allow some womenwith breast cancer to respond better totherapy,” says Dr. McLaughlin. “Anotherteam is studying genetic factors that putsome people at higher risk of high bloodpressure and kidney stones.

“Our work has already led to some realimprovements in health. For example, one team has learned a great deal aboutthe susceptibility of First Nations peopleto diabetes, and is now applying thatknowledge to treat the disease and preventcomplications within the community.”

As scientific knowledge continues toaccumulate, health research is becomingmore and more complex. Recognizingthis, the Centre is building its capacity toundertake large-scale research projects incollaboration with other facilities. “Ourwork is, by its very nature, collaborative,”says Dr. McLaughlin. “We don’t do everything ourselves. Instead, we buildbridges between the many disciplinesneeded to translate scientific discoveriesinto improved human health.”

Quick facts aboutthe ProssermanCentre for HealthResearch

Number of staff: 62

Funding sources: Canada Foundation forInnovation (cfi)

Canadian Institutes ofHealth Research (cihr)


Dr. John McLaughlin (Co-ordinator)

Dr. Laurent Briollais

Dr. Shelley Bull

Dr. Mary Jane Esplen

Dr. Pamela Goodwin

Dr. Julia Knight

Dr. Alexander Logan

Dr. Robin McLeod

Dr. Bernard Zinman


Epidemiology is the study of how disease is distributed andcontrolled in large populations. At the Prosserman Centre forHealth Research, leading epidemiologists and biostatisticiansstudy both individuals and large populations. Their goal is tounderstand the role of genetic and environmental factors indiseases and their treatment.

“

Our work is, by its verynature, collaborative.We buildbridges between the many disciplines needed to translatescientific discoveries intoimproved human health”Dr. John McLaughlin

“

2120

Quick Statistics 2oo4-o5

Canadian Institute of Health Research 35%

Ontario Research and Development Fund 4%

CIHR Indirect Costs 4%

Other Research Sponsors 4%

Genome Canada 15%

Industry Sponsored Research 10%

Infrastructure Programs (CFI/OIT) 14%

MSH Foundation 9%

National Cancer Institute of Canada 5%

Operating Grants 68% Infrastructure Grants 19%


Clinical Trials 2%

Career/Traineeship Awards 4%

Total Research Funding ($64.2 million)

Canadian Institute of Health Research 35%

Ontario Research and Development Fund 4%

CIHR Indirect Costs 4%

Other Research Sponsors 4%

Genome Canada 15%


Infrastructure Programs (CFI/OIT) 14%

MSH Foundation 9%

National Cancer Institute of Canada 5%

Operating Grants 68% Infrastructure Grants 19%


Clinical Trials 2%

Career/Traineeship Awards 4%

Total Research Funding Awarded by Grant Type ($64.2 million)

Number of Personnel

Number of Institute PIs 45

Number of Clinical Researchers 76

Number of trainees 294(Research Fellows, graduate students, undergraduate students)

Number of other research staff 3o4(Technician, administrative staff, clinical staff )

Total number of Personnel 7 ı9

S

Number of Projects

Number of funded Research Projects 576

Number of active clinical protocols 95

Number of salary awards ı ı 8

Total number of Projects 789

S

Selected Financial Information

Total infrastructure grants $ ı ı .8 million

Total research budget 2oo4-o5 $64.2 million

S

22

SLRI Leadership 2oo4-o5

Executive Committee

Chair

Dr. Tony Pawson

Members

Dr. Joseph Culotti

Dr. Jim Dennis

Dr. Steven Gallinger

Dr. Stephen Lye

Dr. John McLaughlin

Dr. John Roder

Dr. Janet Rossant

Dr. Cindy Todoroff (Secretary)

Dr. Mike Tyers

Dr. Bernie Zinman

Scientific Advisory Board

Chair

Sir Keith PetersRegius Professor of Physics Cambridge UniversityCambridge, cb, uk

Members

Dr. Michael Czech Professor, Cell and Molecular Biology University of MassachusettsAmherst, ma, usa

Dr. Brigid Hogan Professor and Chair, Cell Biology Duke University Durham, nc, usa

Dr. Thomas M. Jessell Senior InvestigatorHoward Hughes Medical InstituteColumbia Medical School New York, ny, usa

Dr. Andrey S. Shaw Professor, Molecular Cell Biology Program Washington UniversitySaint Louis, mo, usa

Research Committee

Co-Chairs

Mr. Thomas E. Kierans

Mr. Lawrence Tanenbaum

Members

Mrs. Michael Ann Benzie

Mr. Brian Crombie

Dr. John R. Evans

Mr. Irving R. Gerstein

Mr. Mitchell Kunin

Mr. Joseph Lebovic

Mr. Stephen M. Pustil

Mr. Joseph L. Rotman

Dr. Louis Siminovitch

Clinical

Dr. Alan Bocking

Dr. Zane Cohen

Dr. Allan Detsky

Dr. Kenneth P.H. Pritzker

Dr. Patrice Bret

Ex Officio

Mr. Lawrence S. Bloomberg

Mr. Bernard I. Ghert

Mr. Joseph Mapa

Mr. Edward Sonshine

Mr. Kenneth M. Tanenbaum

Ms. Carol Wilding

Mr. Charles M. Winograd

Leads

Dr. Stephen J. Lye

Dr. Anthony J. Pawson

23

Samuel Lunenfeld Research Institute

The Samuel Lunenfeld Research Institute is truly a scientific and educational jewel. It has been an outstanding breeding ground for research leadership and the site ofwonderful breakthroughs in bioscience since its inception. Today, the Lunenfeldremains a source of great pride for both the Mount Sinai Hospital and the Universityof Toronto academic family in general.

Dr. David NaylorPresident, University of Toronto

S

The research at the Samuel Lunenfeld Research Institute continues to go from strengthto strength. John McLaughlin’s elegant population-based studies on colon cancer in Ontario and Newfoundland, the research of Stephen Lye and his team’s work onpre-eclampsia and pre-term labour, and Mike Tyers’ beautiful work discerning thefunction of all the genes in a single organism are examples of the excellence and relevancethat have characterized slri research from the very beginning.

Dr. Alan BernsteinPresident, Canadian Institutes of Health Research

S

The University of Toronto values immensely its close working relationship with colleagues at affiliated institutions such as the Samuel Lunenfeld Research Institute.The scientific leadership provided by slri investigators, the quality of the trainingenvironment, and the collaborative interactions they foster across the city, are exemplaryin enhancing the investigator profile of the University of Toronto and its hospital affiliates.

Dr. John ChallisVice President, Research, University of Toronto

S

600 University AvenueToronto, Ontario, Canada m5g 1x5 Tel: 416.586.5065 Fax: 416.586.8555 www.mtsinai.on.ca

Mount Sinai Hospital’s Samuel Lunenfeld Research Instituteis committed to excellence in health research, the training ofyoung investigators, and a culture of research-based medicineboth within the Hospital and the Institute.

Dr. Zane Cohen, centre, Surgeon-in-Chief and world-renowned gastro-intestinal specialist, performs surgery at Mount Sinai Hospital, where leading-edge research comes togetherwith excellence in patient care. For example,researchers from Mount Sinai’s SamuelLunenfeld Research Institute have discoveredthat the mutation of a specific gene in somepatients with colon cancer indicates a risk ofacquiring the disease.

a0262 7june ms ar 16pgs - mount sinai hospital · of our labs is developing a blood test to...

Documents